DB-1310 by Duality Biologics (Shanghai) for Non-Small Cell Lung Cancer: Likelihood of Approval

DB-1310 is under clinical development by Duality Biologics (Shanghai) and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Challenges: Test Your Knowledge on Pediatric Vaccines

A MedPage Today Clinical Challenges series discussed three areas of pediatric vaccines: vaccinating children with needle phobia, handling vaccine hesitancy among parents, and navigating new

November 11, 2023

FDA to host adcomm on PD-L1 as a predictive biomarker for checkpoint inhibitors

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

August 23, 2024

Rare gene variants linked to Type 2 diabetes discovered in Asian Indian families

A new study published in Communications Medicine, a Nature publication, details the discovery of rare gene variants that increase the prevalence of Type 2 diabetes

February 26, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.